iNtODEWORLD

by Bacteriophage.news
Bacteriophage.news Company Biotechnology Research and Development iNtODEWORLD
Category

iNtODEWORLD is a subsidiary company of iNtRON Biotechnology with a focus on global research and development investment, focusing on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies.  iNtODEWORLD utilizes bacteriophage-based technology to develop endolysin-related technologies for animal health and human health. The company is focusing on using endolysin to target Gram-Negative bacteria that are particularly problematic including; SalmonellaAcinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Their BACASEs target Gram-negative bacteria and are based on N-Rephasin technology.

Endolysin bacteriophage-based product pipeline:

Candidate Endolysins targeting Gram-negative bacteria

  • NPA-EL200 – developed using the genetic information of an Escherichia coli bacteriophage and degrades the peptidoglycan linkages found in Salmonella, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia.
  • NPA-TL200 – developed using the genetic information of an Escherichia coli bacteriophage and degrades the peptidoglycan linkages found in Salmonella, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia.
  • NPA-SJ200 – developed using the genetic information of a Salmonella bacteriophage and degrades the peptidoglycan linkages found in Salmonella, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia.
  • SEL-2 – developed using the genetic information of a Salmonella bacteriophage and degrades the peptidoglycan linkages found in Salmonella, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia.
  • NPA-CH200 – developed using the genetic information of an Escherichia coli bacteriophage and degrades the peptidoglycan linkages found in Salmonella, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia.

Endolysin bacteriophage-based development programs:

Endolysin Bio-drugs that target Gram-positive bacteria

  • Methicillin-resistant Staphylococcus aureus (MRSA) infection treatment
  • Vancomycin-resistant Staphylococcus aureus (VRSA) infection treatment
  • Vancomycin-resistant Enterococcus (VRE) infection treatment
  • Penicillin-resistant Streptococcus pneumoniae (PRSP) infection treatment

This website uses cookies. Accept Read More